About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's product candidate, ATX-101, is an injectable drug currently in Phase III clinical development for the reduction of submental fat, which commonly presents as a "double chin."
CONTACT: Jennifer Knapp         +1 212 401 8916         Jennifer.Knapp@nasdaqomx.com

company logo

If you liked this article you might like

Walt Disney, Tiffany, NASDAQ, Mazor Robotics: 'Mad Money' Lightning Round

A Ferocious Rotation: Cramer's 'Mad Money' Recap (Friday 6/9/17)

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

The Stock Market Has Been Amazingly Resilient -- Check Out These 10 Charts